文献速递头颈与中枢神经肿瘤

激光间质热疗治疗脑肿瘤:LAANTERN 前瞻性多中心分析

Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.
PubMed 文献 · J Clin Oncol · 2026-08-17

基于 LAANTERN 前瞻性多中心注册研究(25 家美国中心,2015–2023 年),分析 787 例原发(445 例)与转移性脑肿瘤(342 例)患者接受激光间质热疗的临床结局。结果显示中位住院 32.4 小时、62.6% 避免 ICU 入住、不良事件率 12.8%、死亡率 0.25%,生活质量至术后 3 年保持稳定;高级别胶质瘤和复发转移瘤中更大消融范围与更小病灶与生存改善相关。

要点

  • LITT 治疗原发与转移性脑肿瘤住院时间短、并发症率低、功能状态得以保持。
  • 高级别胶质瘤中更大消融范围、转移瘤中更小病灶体积与生存改善相关。
  • 术后 30%–40% 患者停用抗癫痫药,80% 停用类固醇,生活质量至 3 年稳定。

核心结论

  • 这一最大规模前瞻性 LITT 队列支持将 LITT 作为原发与转移性脑肿瘤的减瘤工具,具有住院时间短、并发症率低和功能状态保持的特点。
  • 胶质母细胞瘤的消融范围与转移性疾病的病灶体积可能成为指导患者选择的因素。

研究设计与样本

  • LAANTERN 前瞻性多中心注册研究(ClinicalTrials.gov NCT02392078),纳入 2015 至 2023 年间 25 家美国中心的肿瘤患者。
  • 分析纳入所有使用 Monteris NeuroBlate 系统接受 LITT 的原发或转移性脑肿瘤患者,前瞻性收集人口学、术中数据、不良事件、生存及功能状态数据。
  • 共纳入 787 例患者,其中原发脑肿瘤 445 例、转移性脑肿瘤 342 例;中位年龄 59.6 岁,儿童中位年龄 15 岁(n=18)。
  • 采用单因素和多因素分析。

主要发现

  • 中位住院时间 32.4 小时,62.6% 的患者避免入住重症监护室。
  • 不良事件率为 12.8%,其中 65.5% 的事件被认为是一过性的;死亡率为 0.25%。
  • 30%–40% 的患者停用抗癫痫药,80% 的患者在 LITT 后停用类固醇。
  • 生活质量在 LITT 后至 3 年保持稳定。
  • 在高级别胶质瘤和复发转移瘤患者中,更大的消融范围(EOA)和更小的病灶尺寸与生存结局的显著改善相关。

关键数值与推荐

  • 原发脑肿瘤 445 例,转移性脑肿瘤 342 例,合计 787 例。
  • 中位住院时间 32.4 小时,62.6% 避免 ICU 入住,不良事件率 12.8%(其中 65.5% 为一过性),死亡率 0.25%。
  • 30%–40% 患者停用抗癫痫药,80% 患者停用类固醇,生活质量稳定至术后 3 年。
  • 高级别胶质瘤中更大 EOA 与更小病灶、复发转移瘤中更小病灶与生存改善显著相关。

临床怎么用

  • LITT 可作为原发与转移性脑肿瘤的减瘤选择,尤其适合希望缩短住院时间、降低并发症风险并保持功能状态的患者。
  • 在高级别胶质瘤中应关注消融范围(EOA),在转移性病灶中应关注病灶体积,以辅助患者选择。
  • 术后多数患者可停用抗癫痫药和类固醇,生活质量至 3 年保持稳定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Laser interstitial thermal therapy is a surgical tool used to ablate brain tumors, radiation necrosis, and epileptic foci. Data from the LAANTERN prospective multicenter registry (ClinicalTrials.gov identifier: NCT02392078), containing patients with tumor from 25 US centers between 2015 and 2023, were analyzed to determine clinical outcomes. METHODS: All patients with primary or metastatic brain tumors treated with LITT using the Monteris NeuroBlate System were included in this analysis. Demographics, intraprocedural data, adverse events, survival data, and data pertaining to functional status over time were prospectively collected and then analyzed. Both univariable and multivariable analyses were performed. RESULTS: A total of 787, primary (445) and metastatic brain tumor (342), patients were included. The median age was 59.6 years and the median pediatric age 15 years (n = 18). The median length of hospital stay was 32.4 hours, and 62.6% avoided intensive care unit admission. The adverse event rate was 12.8%, with 65.5% of events considered transient. Mortality rate was 0.25%. Anticonvulsants were stopped in 30%-40% of patients, and 80% of patients stopped steroids after LITT. Quality of life remained stable up to 3 years post-LITT. Greater extent of ablation (EOA) and smaller lesion size were associated with significant improvements in survival outcomes in patients with high-grade glioma and recurrent metastases. CONCLUSION: The data from this largest, prospective LITT cohort support the consideration of LITT as a cytoreductive tool for patients with primary and metastatic tumor with short hospital stays, low complication rates, and preserved functional status. The EOA in glioblastoma and lesion volume in metastatic disease emerge as factors that may guide patient selection.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Leuthardt EC, Chiang V, Hadjipanayis CG, et al. Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study. J Clin Oncol. 2026. PMID: 42607280. doi:10.1200/JCO-25-02604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。